Sharen schreef op 6 december 2021 16:02:
Vandaag een positief artikel over de inmiddels verbeterde beleggings-waarde van small-medium sized biotech bedrijven:
seekingalpha.com/amp/article/4473586-...“ Bottom Line:
As the aforementioned November developments suggest some relief from this year’s largest headwinds, small- and mid-capitalization biotechnology companies could benefit from a recovery considering their higher growth potential in a stabilized market, in addition to benefiting from easier comps in 2021 relative than their larger-cap counterparts.
For investors who can tolerate higher risk in exchange for higher return potential, the small- to mid-cap biotechnology space may prove interesting in the coming months as the initial shock of regulatory fears is quelled and FDA processes are normalized under a new commissioner.”